<DOC>
	<DOCNO>NCT00395707</DOCNO>
	<brief_summary>The primary objective study determine safety &amp; efficacy ranibizumab treatment retinal angiomatous proliferation secondary age relate macular degeneration .</brief_summary>
	<brief_title>Study To Determine Safety/Efficacy Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration</brief_title>
	<detailed_description>This study phase I/II open label interventional case series . Twenty patient retinal angiomatous proliferation randomize receive intravitreal ranibizumab dose 0.3mg/0.05 ml 0.5mg/0.05 ml . Patients receive ranibizumab via par plana injection monthly basis total duration therapy 12 month . Patients follow complete 12-month treatment course .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study . Age &gt; 50 year Definite characteristic sign age relate macular degeneration include drusen Presence retinal angiomatous proliferation determine clinical sign ( intra retinal hemorrhage , retinal edema , cystic retinal edema ) angiography ( occult leakage fluorescein angiography , hot spot static ICG , visible RAP lesion high speed ICG ) Prior treatment verteporfin , externalbeam radiation therapy , transpupillary thermotherapy study eye ( predominantly classic CNV however include subject 3 prior PDT treatment ) Treatment verteporfin nonstudy eye le 7 day precede Day 0 Previous participation clinical trial ( either eye ) involve anti angiogenic drug ( pegaptanib , ranibizumab , anecortave acetate , protein kinase C inhibitor , etc . ) Previous subfoveal focal laser photocoagulation involve foveal center study eye Laser photocoagulation ( juxtafoveal extrafoveal ) study eye within 1 month precede Day 0 History vitrectomy , submacular surgery , surgical intervention AMD study eye Previous participation study investigational drug within 1 month precede Day 0 ( exclude vitamin mineral )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Macular Degeneration</keyword>
	<keyword>Age Related Macular Degeneration</keyword>
	<keyword>Retinal Angiomatous Proliferations</keyword>
</DOC>